logo ecco

logo ecco

Portal
  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter

ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Oral presentations: Scientific Session 1: Hot debates in IBD (2020)

OP03 Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s disease: Long-term follow-up of the LIR!C trial

T. Stevens MD1, L. Haasnoot1, G. D’Haens1, C. Buskens2, E.J. de Groof2, E. Eshuis1, T. Gardenbroef3, B. Mol1, P. Stokkers3, W. Bemelman2, C. Ponsioen1, LIR!C

1Department of Gastroenterology and Hepatology, Amsterdam UMC- location AMC, Amsterdam, The Netherlands, 2Department of Surgery, Amsterdam UMC- location AMC, Amsterdam, The Netherlands, 3Department of Gastroenterology and Hepatology, OLVG, Amsterdam, The Netherlands

Background

The LIR!C trial showed that laparoscopic ileocaecal resection is at least as good as anti-TNF in terms of quality of life and is cost-saving. Current aims were to compare the long-term outcome of both interventions and to identify factors associated with the failure of the initial therapeutic strategy.

Methods

Long-term data were retrospectively collected for patients who participated in the LIR!C trial, a multicentre, randomised controlled trial that compared a laparoscopic ileocaecal resection with infliximab for adult patients with non-stricturing and immunomodulator refractory ileocaecal Crohn’s disease. Outcomes of interest needed for (re-)surgery or anti-TNF, duration of treatment effect as well as the identification of factors associated with sustained treatment effect. The treatment effect was defined as the time without the need for additional Crohn-related treatment. Potential factors were defined a priori and analysed by multivariable Cox regression analysis.

Results

Median follow-up time was 63.5 [IQR 39 – 94.5] months. In the resection group, 18 (26.1%) patients started anti-TNF treatment while none of the patients required a second resection (Figure 1). Twenty-nine (42%) patients did not require additional Crohn-related treatment. In contrast, in the infliximab group, 31 (47.7%) patients underwent a Crohn-related resection. Duration of treatment effect was similar with a median (95% CI) time without additional treatment of 33 (15.1–50.9) and 34 (0–69.3) months in the resection and infliximab group respectively (log-rank p = 0.521). In both groups, prophylactic immunomodulators decreased the risk of additional treatment (HR 0.34 95% CI (0.16–0.69) and HR 0.49 95% CI (0.26–0.93), respectively).

Figure 1. Need for anti-TNF and (re-)surgery

Conclusion

This long-term follow-up study of the LIR!C trial showed that after a median follow-up of 5 years the majority of patients who underwent resection were free of anti-TNF treatment, none required a second resection and almost half were free of any additional medical treatment for disease flares. Conversely, almost half of the patients in the infliximab group moved on to a Crohn-related resection. These data support early ileocaecal resection in Crohn’s disease patients not responding to conventional treatment.

  • Posted in: Oral presentations: Scientific Session 1: Hot debates in IBD (2020)
Logo_contact.png     T: +43 (0)1 710 22 42-0
F: +43 (0)1 710 22 42-001
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Home
  • Sitemap
  • Contact
  • Imprint
  • Data privacy statement
  • Media Policy

  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter